3-(2-hydroxyethyl)-2-methylbenzo[4,5]imidazo[1,2-a]pyrimidin-4(10H)-one | 478028-94-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 3-(2-hydroxyethyl)-2-methylbenzo[4,5]imidazo[1,2-a]pyrimidin-4(10H)-one
• 英文别名: 3-(2-hydroxyethyl)-2-methylbenzimidazolo[3,2-a]pyrimidin-4(1H)-one；3-(2-hydroxyethyl)-2-methyl-1H-pyrimido[1,2-a]benzimidazol-4-one
• CAS: 478028-94-3
• 化学式: C₁₃H₁₃N₃O₂
• 分子量: 243.265
• InChiKey: SRVUPICOOHNSET-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  67.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(2-hydroxyethyl)-2-methylbenzo[4,5]imidazo[1,2-a]pyrimidin-4(10H)-one 在 三氯氧磷 作用下， 以 水 为溶剂， 反应 5.5h， 生成 2-methyl-3-(2-(methylamino)ethyl)benzo[4,5]imidazo[1,2-a]pyrimidin-4(10H)-one
  参考文献：
  名称：

  MRGX Receptor Antagonists

  摘要：

  该发明涉及一种用于预防或治疗与MrgX2受体相关的疾病或紊乱的方法。该发明还涉及MrgX2拮抗剂及其生理上可接受的盐。该发明还涉及包含MrgX2拮抗剂的药物组合物和剂型。

  公开号：

  US20210128561A1
• 作为产物：
  描述：

  3-(2-acetoxyethyl)-2-methylbenzimidazolo[3,2-a]pyrimidin-4(1H)-one 在 sodium ethanolate 作用下， 以 乙醇 为溶剂， 反应 1.0h， 以80%的产率得到3-(2-hydroxyethyl)-2-methylbenzo[4,5]imidazo[1,2-a]pyrimidin-4(10H)-one
  参考文献：
  名称：

  以环状β-酮内酯为结构单元合成苯并杂[3,2-a]嘧啶

  摘要：

  摘要实现了高产率（80-85％）合成3-（2-取代的乙基）-2-甲基苯并杂[3,2- a ]嘧啶的新方法，该方法涉及一种容易从β-得到的二氢呋喃酮中间体。酮内酯转化为2-氨基苯并杂环。该方法的主要优点是高产率和产物纯度。 图形概要

  DOI：

  10.1007/s00706-008-0062-x

文献信息

• NOVEL SUBSTITUTED TETRACYCLIC IMIDAZOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE AS A MEDICINE
  申请人：Janssen Pharmaceutica NV

  公开号：EP1401838B1

  公开（公告）日：2014-03-26
• THE USE OF ANTI-HISTAMINICS FOR ACUTE REDUCTION OF ELEVATED INTRACRANIAL PRESSURE
  申请人：JANSSEN PHARMACEUTICA N.V.

  公开号：EP1451196A1

  公开（公告）日：2004-09-01
• The use of substituted tetracyclic imidazole derivatives as anti-histaminics
  申请人：JANSSEN PHARMACEUTICA N.V.

  公开号：EP1451196B1

  公开（公告）日：2007-08-15
• Novel substituted tetracyclic imidazole derivatives, processes for their preparation, pharamaceutical compositions comprising them and their use as a medicine
  申请人：——

  公开号：US20040167138A1

  公开（公告）日：2004-08-26

  The invention concerns novel substituted tetracyclic imidazole derivatives useful for the treatment of elevated intracranial pressure (ICP) and/or secondary ischaemia, in particular caused by brain injury, more in particular caused by traumatic (TBI) and non-traumatic brain injury, processes for their preparation, pharmaceutical compositions comprising them and their use as a medicine. The novel compounds comprise compounds according to the general Formula (I), the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof and the N-oxide form thereof. In particular, the preferred compound is 3-[2-[4-(11,12-dihydro-6H-benzimidazo[2,1-b][3]benzazepin-6-yl)-2-(phenylmethyl)-1-piperidinyl]ethyl]-2,10-dimethyl pyrimido[1,2-a]benzimidazol-4(10H)-one, the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof and the N-oxide form thereof. 1
• Use of anti-histaminics for acute reduction of elevated intracranial pressure
  申请人：Tegtmeier Frank

  公开号：US20050070525A1

  公开（公告）日：2005-03-31

  The invention concerns a novel histamine receptor antagonist and the use of an histamine receptor antagonist for the reduction of intracranial pressure (ICP), in particular for the prevention and treatment of elevated intracranial pressure and/or secondary ischaemida, in particular caused by brain injury, more in particular caused by traumatic (TBI) and non-traumatic brain injury. The novel compounds comprise compounds according to the general Formula (I) the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof and the N-oxide form thereof. In particular, the preferred compound is 3-[2-[4-(11,12-dihydro-6H-benzimidazo[2,1-b][3]benzazepin-6-yl)-2-(phenyl-methyl)-1-piperidinyl]ethyl]-2,10-dimethyl pyrimido[1,2-α]benzimidazol-4(10H)-one, the pharmaceutically acceptable acid or base addition salts thereof, the stereochemically isomeric forms thereof and the N-oxide form thereof. Also claimed is the novel use of commercially available histamine H1-and H2-receptor antagonists for the reduction of intracranial pressure (ICP).